Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.54 |
| ▸ | BCR | P11274 | 4/20 | 0.54 |
| ▸ | TACR3 | P29371 | 14/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.49 |
| ▸ | ERG | P11308 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | TACR2 | P21452 | 3/20 | 0.48 |
| ▸ | TACR1 | P25103 | 3/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4702400 | 0.89 | ABL1 (0.47) | ABL1BCRTACR3KCNH2ERG | |
| SCHEMBL4700021 | 0.82 | CHRNA7 (0.45) | CHRNA7 | |
| SCHEMBL4702987 | 0.81 | CHRNA7 (0.44) | ABL1BCRCHRNA7 | |
| SCHEMBL4700437 | 0.81 | CHRNA7 (0.55) | CHRNA7 | |
| SCHEMBL4703166 | 0.81 | CHRNA7 (0.49) | TACR3CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4702404 | 0.80 | CHRNA7 (0.54) | ABL1BCRTACR3CHRNA7 | |
| SCHEMBL4705060 | 0.79 | CHRNA7 (0.48) | CHRNA7 | |
| SCHEMBL4701453 | 0.79 | ALDH1A1 (0.56) | CHRNA7 | |
| SCHEMBL4701749 | 0.78 | CHRNA7 (0.45) | CHRNA7 | |
| SCHEMBL4030570 | 0.77 | CHRNA7 (0.60) | CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539765-B1 | BIARYL DIAZABICYCLOALKANE AMIDES AS NICOTINIC ACETYLCHOLINE AGONISTS | ASTRAZENECA AB (SE) | 2008-12-10 | — | — | EP | claimed |
| US-20050239774-A1 | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | claimed |
| EP-1539765-B1 | BIARYL DIAZABICYCLOALKANE AMIDES AS NICOTINIC ACETYLCHOLINE AGONISTS | ASTRAZENECA AB (SE) | 2008-12-10 | — | — | EP | disclosed |
| US-20050239774-A1 | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239774-A1 | Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists | CHRNA1, CHRNB1, CHRNA2 | ABL1 3065/4885BCR 2646/4885TACR3 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.